Skip to main content
. 2022 Apr 12;13:1970. doi: 10.1038/s41467-022-29539-3

Fig. 5. Th17 cells are enriched in the synovial fluid (SF) of patients who develop arthritis after combined immune checkpoint inhibitor (ICI) therapy.

Fig. 5

a Percentage of CD4+ T cells in SF producing key effector cytokines (upper panels) and percentage of Th1, transient (t-)Th17, and Th17 cells (lower panels). Two-sided unpaired t test. *P < 0.05. Bars indicate the mean and SEM. IFNγ, interferon gamma; IL, interleukin. See Supplementary Table 2 for demographic and clinical profiles of patients who developed arthritis after PD-1 inhibitor monotherapy (PD-1 inhibitor arthritis; P in the figure) and patients who developed arthritis after combined CTLA-4 and PD-1 inhibitor therapy (combined ICI arthritis; C in the figure). n = 6 from the PD-1 arthritis group and 5 from the combined ICI arthritis group. b Percentage of CD8+ T cells in SF producing key effector cytokines (upper panels) and percentage of Tc1, t-Tc17, and Tc17 cells (lower panels). Two-sided unpaired t test. Bars indicate the mean and SEM. n = 6 from the PD-1 arthritis group and 5 from the combined ICI arthritis group. c Frequencies of Th1/Tc1, t-Th17/t-Tc17, and Th17/Tc17 cells in 4 peripheral blood (PB) and matching SF samples. Two-sided paired t test. Source data are provided as a Source Data file.